SCHEMBL7206608

SCHEMBL7206608

Cc1ccc(C2CCN(S(=O)(=O)C3CCNCC3(O)C(=O)NO)CC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP5 P45974 1/20 0.41
MMP13 P45452 5/20 0.40
MMP1 P03956 2/20 0.38
MMP3 P08254 2/20 0.38
MMP2 P08253 5/20 0.36
ADAM10 O14672 3/20 0.36
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35
ADAM17 P78536 1/20 0.35
MMP9 P14780 2/20 0.35
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SLC18A3 Q16572 1/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7205721 0.89 MMP13 (0.45) USP5MMP13MMP1MMP3MMP2
SCHEMBL7204534 0.89 USP5 (0.41) USP5MMP13MMP3MMP2ADAM10
SCHEMBL7201610 0.89 MMP2 (0.47) USP5MMP13MMP1MMP3MMP2
SCHEMBL7207178 0.89 USP5 (0.43) USP5MMP13MMP1MMP3MMP2
SCHEMBL7202601 0.88 MMP2 (0.49) USP5MMP13MMP1MMP3MMP2
SCHEMBL7205659 0.87 TP53 (0.41) MMP13MMP1MMP3MMP2ADAM10
SCHEMBL7205477 0.85 ADAM17 (0.41) MMP13MMP3MMP2ADAM10ADAM17
SCHEMBL7200991 0.85 MMP13 (0.43) MMP13MMP1MMP2ADAM17SMN1; SMN2
SCHEMBL7205516 0.83 ADAM10 (0.51) MMP13MMP1MMP2ADAM10DRD4
SCHEMBL7208005 0.83 MMP13 (0.42) MMP13MMP1MMP2ADAM10ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 USP5 1778/4885MMP13 4/4885MMP1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.